IOF Proof of concept project: Innervate 3D ultra-stretchable electronics low volume fabrication Hasselt University
In-vivo proof of concept of microbubbles based non-invasive dosimetry for radiotherapy treatment. KU Leuven
Cancer remains a major public health problem in the world which necessitates the need for further technological innovation towards effective treatment strategies. Next to surgery and chemotherapy, an important treatment option is radiotherapy in which tumor cells are destroyed by ionizing radiation. Although modern radio therapeutic treatment strategies have become very efficient by reducing radiation to adjacent (healthy) tissue whenever ...
Clinical proof of concept through a randomised phase II study: a combination of immunotherapy and stereotactic ablative radiotherapy as a curative treatment for limited metastatic lung cancer KU Leuven
IMMUNOSABR is geared towards opening up a new paradigm in treating metastatic cancer by obtaining clinical proof of concept for a novel bi-modal curative treatment strategy. High precision stereotactic ablative radiotherapy (SABR) is combined with immunotherapy to form a powerful synergistic anti-tumour strategy. The approach relies on the direct cytotoxic effect of SABR, the abscopal effect of radiation observed at distance from the ...
A proof of concept study for a novel mechanism of action to combat osteoporosis by inhibiting osteoclastogenesis Ghent University
Excessive bone resorption by osteoclasts can lead to disability as well in inflammation induced bone erosion such as Rheumatoïd Arthritis as in non-inflammation dependent bone diseases such as postmenopausal osteoporosis. We have shown that sialoadhesin has a role in osteoclastogenesis as its deficiency or blocking inhibits osteoclastogenesis ex vivo in mouse and human and in vivo in mice, either non-diseased or during arthritis. Based on ...
Exploring the role of non-coding variation in inherited retinal dystrophies: NMNAT1 regulatory mutations as a proof of concept Ghent University
Inherited retinal dystrophies (RDs) are a major cause of early-onset blindness worldwide. The
currently known genetic defects account for ~50% of RD cases and are mostly located in the coding
portion of the genome. However, there is accumulating evidence that a large proportion of
mutations reside in non-protein-coding regions, the so-called U+201Cunk DNAU+201D Thus far, several deepintronic
mutations have ...